Quantcast

Latest GlaxoSmithKline Stories

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK's first once-daily anticholinergic, a type of...

2014-04-30 08:33:26

LONDON, April 30, 2014 /PRNewswire/ -- SOURCE GlaxoSmithKline

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...

2014-04-28 08:32:52

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro(TM) Ellipta(®) (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies...

2014-04-24 23:06:13

Healthcare market research firm Kalorama Information says the pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. New York, NY (PRWEB) April 24, 2014 Healthcare market research firm Kalorama Information says the pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline....

2014-04-24 12:30:22

PARSIPPANY, N.J., April 24, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today proposed regulation of electronic cigarettes (e-cigarettes), pipes, cigars and other nicotine-delivering products subject to FDA's jurisdiction through the Center for Tobacco Products (CTP). As leaders in smoking cessation, GlaxoSmithKline Consumer Healthcare (GSKCH) recognizes FDA's proposal as a good first step in regulating these nicotine products. We especially commend FDA on...

2014-04-16 08:27:53

Analysis points to three potential blockbusters: Sovaldi, Anoro Ellipta and Idelalisib entering market this year PHILADELPHIA, April 16, 2014 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, released its annual forecast of the leading drugs to watch in 2014, including three potential blockbuster treatments anticipated to attain more than $1 billion in sales through...

2014-04-15 08:29:35

OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ -- Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050. PSX1001 and PSX1050, which are the first products to emerge from Prosonix's...

2014-04-14 16:24:28

LONDON, April 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:China Pharmaceuticals and Healthcare Report Q1 2014Includes 3 FREE quarterly updatesBMI View:Multinational pharmaceutical firms' commitment to the Chinese market is underpinned by thepotential of the healthcare sector. The sector itself is supported by consistent government efforts, therebyincreasing patients' access to these drugs. We would also highlight risks of operating in China, such as...

No Evidence That Tamiflu Reduces Flu Complications, ER Admissions
2014-04-10 09:38:58

Lawrence LeBlond for redOrbit.com - Your Universe Online Tamiflu is widely used to help patients relieve symptoms of influenza. While the drug – generically known as oseltamivir – can shorten symptoms by about half a day, there is no good evidence to support claims that it reduces admissions to the ER or complications of influenza. The new findings come from the Cochrane Collaboration, an independent, global healthcare research network, and the British Medical Journal. There had...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related